Journey Medical Corporation
DERM
Positions held
Your positionsDERM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $167.94M | Enterprise value | $167.83M | Trailing P/E | — | Forward P/E | -99.17 |
| PEG | — | Price / book | 5.12 | Beta | 1.11 | Dividend yield | 0.00% |
| Revenue growth | 23.3% | Earnings growth | — | Gross margin | 65.5% | Operating margin | 2.5% |
| Profit margin | -9.0% | ROE | -23.8% | ROA | -2.1% | Debt / equity | 0.80 |
| Current ratio | 1.59 | Free cash flow | -$5.46M | Analyst recommendation | strong_buy | Mean target | $13.75 |
| 52w high | $9.56 | 52w low | $4.31 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $18.5M | $16.0M | $16.1M | $17.6M | $15.0M | — |
| Op margin | 2.5% | -9.3% | -2.8% | -8.7% | -19.2% | — |
| Net income | -$0.3M | -$2.2M | -$1.2M | -$2.3M | -$3.8M | — |
| Gross margin | 66.8% | 61.0% | 66.2% | 67.4% | 67.1% | — |
| Gross profit | $12.4M | $9.7M | $10.6M | $11.9M | $10.1M | — |
| Operating income | $0.5M | -$1.5M | -$0.4M | -$1.5M | -$2.9M | — |
- Revenue +16% vs prior quarter ($19M vs $16M).
- Gross margin 66.8% (was 61% prior quarter).
- Operating margin expanded to 2.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $61.9M | $56.1M | $79.2M | $73.7M | — |
| Op margin | -13.2% | -32.5% | 1.4% | -37.4% | — |
| Net income | -$11.4M | -$14.7M | -$3.9M | -$29.6M | — |
| Gross margin | 66.2% | 62.8% | 71.1% | 58.2% | — |
| Gross profit | $40.9M | $35.3M | $56.3M | $42.9M | — |
| Operating income | -$8.2M | -$18.2M | $1.1M | -$27.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-21 · Are Options Traders Betting on a Big Move in Journey Medical Stock?
2026-09-08 · Journey Medical Corporation to Participate in September 2026 Investor Conferences
2026-08-25 · ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
2026-08-19 · Journey Medical (DERM) Q2 2026 Earnings Call Transcript
2026-08-19 · Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
2026-08-13 · --B. Riley Adjusts Journey Medical Price Target to $15 From $12, Maintains Buy Rating
2026-08-13 · Journey Medical Corp (DERM) (Q2 2026) Earnings Call Highlights: Emrosi Surges 20% Sequentially, ...
2026-08-13 · Journey Medical Corporation Q2 2026 Earnings Call Summary
2026-08-12 · Fortress Biotech Q2 Earnings Call Highlights
2026-08-12 · Journey Medical Q2 Earnings Call Highlights
2026-08-12 · Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings
Price (daily)
Full chart · RSI · MACD · patterns